NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Canton Strategic Holdings, Inc. (CNTN) Stock Analysis

Canton Strategic Holdings, Inc. (CNTN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CNTN

$2.28

+$0.03 (+1.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNTN with… →

CNTN Key Statistics

As of Sep 4, 2026
Trading
Open
$2.21
Previous Close
$2.25
Day's Range
2.18–2.30
52-Week Range
1.75–6.89
Volume
409.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$181.67M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
121.45
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$35.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
79.68M
1-Year Return
−42.86%
Dividend and dates
Avg Volume
923.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CNTN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.75%
2025+49.26%
2024−73.41%
2023−94.78%
2022−88.79%

As of September 4, 2026.

CNTN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$35.92M—
2024$0.00−$12.20M—
2023$0.00−$9.32M—
2022$0.00−$8.47M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.11M−$35.92M—
2024$0.00—−$12.43M−$12.20M—
2023$0.00—−$9.46M−$9.32M—
2022$0.00—−$6.88M−$8.47M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CNTN Valuation vs Biotechnology Median

Median of 656 stocks
MetricCNTNBiotechnology medianvs median
P/S ratio121.4515.268.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Canton Strategic Holdings, Inc. (CNTN) at $181.67M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12.

Over the past 52 weeks the price has ranged from $1.75 to $6.89. The most recent close on file for CNTN is $2.28, dated September 4, 2026. That is +$0.03 (+1.33%) against the previous close. The latest close sits 30.29% above that 52-week low.

Financial Health

In fiscal 2025, Canton Strategic Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $35.92M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 121.45 times revenue. On price-to-sales that is 8 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.5. Annualized volatility over the trailing 4 years is 175.21%. Over the trailing twelve months the price has returned −42.86%. Across 3 years the annualized return works out at −70.67%.

Growth & Income

No dividend is on file for CNTN.

The strongest complete calendar year on file is 2025 at +49.26%; the weakest is 2023 at −94.78%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the price is −24.75%.

Peer Comparison

Canton Strategic Holdings, Inc. (CNTN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Canton Strategic Holdings, Inc. CNTN $181.67M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Canton Strategic Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.

Visit website →